Another piece of bad news has come out for St. Jude Medical (NYS: STJ) regarding an FDA report on defibrillator lead Durata, bringing shares down 12%. In this video, Motley Fool health-care analyst David Williamson talks about how these findings add to a recent string of product difficulties for St. Jude, and how, as an investor, if you see this as the company turning a corner, then it could be a cheap entry point.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article More Bad News for St. Jude originally appeared on Fool.com.
Brenton Flynn and David Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of Medtronic and St. Jude Medical. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.